A
ARTELO BIOSCIENCES, INC.
ARTLCIK 0001621221NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-12.88M
Total Assets
$2.80M
Equity
$-1.27M
Shares Out
2.12M
Op. Cash Flow
$-8.52M
Business
ARTELO BIOSCIENCES, INC. is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Its main product candidates include a dual cannabinoid GPCR agonist (ART27.13) for cancer-related anorexia, a FABP5 inhibitor series led by ART26.12 for neuropathy, oncology and other indications, and a proprietary CBD cocrystal (ART12.11). The company operates through discovery, in-licensing and clinical development activities and leverages academic and industry partnerships. It pursues regulatory approvals and plans to commercialize products via prescription and physician-directed channels across multiple countries.
Summary from filing dated 2025-03-03
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| General and administrative | 6 | 4 | 4 | 6 | 6 | |
| Research and development | 5 | 6 | 6 | 4 | 4 | |
| Total Operating Expenses | 11 | 10 | 10 | 10 | 9 | |
| Loss from Operations | −11 | −10 | −10 | −10 | −9 | |
| Gain on investment | 22,000 | 0 | — | — | — | |
| Interest expense | −194,000 | 0 | 0 | −5,000 | — | |
| Interest expense - related party | −83,000 | 0 | — | — | — | |
| Loss on extinguishment of debt | −825,000 | 0 | — | — | — | |
| Loss on extinguishment of debt - related party | −333,000 | 0 | — | — | — | |
| Net change in fair value of digital assets | −62,000 | 0 | — | — | — | |
| Net change in fair value of trading marketable securities | 0 | 282,000 | 641,000 | — | — | |
| Total other (expense) income | −1 | 282,000 | 641,000 | 204,000 | 10,000 | |
| Provision for income taxes | 0 | 0 | 0 | 0 | 0 | |
| NET LOSS | −13 | −10 | −9 | −10 | −9 | |
| Foreign currency translation adjustments | −70,000 | 1,000 | 51,000 | −212,000 | −54,000 | |
| Total Other Comprehensive Income (Loss) | −70,000 | 1,000 | 51,000 | — | — | |
| TOTAL COMPREHENSIVE LOSS | −13 | −10 | −9 | −10 | −9 | |
| Basic and Diluted Loss per Common Share | −12.52 | −18.3 | −3.14 | — | — | |
| Basic and Diluted Weighted Average Common Shares Outstanding | 1 | 537,000 | 3 | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 600,000 | 2 | 3 | 7 | 12 | |
| Prepaid expenses and other current assets | 95,000 | 219,000 | 554,000 | 789,000 | — | |
| Total Current Assets | 695,000 | 3 | 11 | 18 | 25 | |
| Operating lease right-of-use assets | 64,000 | 99,000 | 21,000 | 60,000 | 81,000 | |
| Intangible asset | 2 | 2 | 2 | 2 | 2 | |
| Other assets | 3,000 | 3,000 | 3,000 | 3,000 | — | |
| TOTAL ASSETS | 3 | 5 | 13 | 20 | 28 | |
| Accounts payable and accrued liabilities | 3 | 2 | 1 | 905,000 | 975,000 | |
| Due to related parties | 345,000 | 61,000 | 30,000 | — | — | |
| Operating lease liabilities - current portion | 40,000 | 35,000 | 23,000 | 40,000 | 31,000 | |
| Accrued interest - convertible notes | 11,000 | 0 | — | — | — | |
| Accrued interest - convertible notes - related party | 4,000 | 0 | — | — | — | |
| Convertible notes | 437,000 | 0 | — | — | — | |
| Convertible notes - related party | 172,000 | 0 | — | — | — | |
| Total Current Liabilities | 4 | 2 | 1 | 998,000 | 1 | |
| Operating lease liabilities | 29,000 | 69,000 | 0 | 23,000 | 57,000 | |
| TOTAL LIABILITIES | 4 | 2 | 1 | 1 | 1 | |
| Preferred Stock, par value $0.001, 69,444 shares authorized, 0 shares issued and outstanding as of December 31, 2025, and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common Stock, par value $0.001, 500,000,000 shares authorized and 2,018,746 and 567,582 shares issued and outstanding as of December 31, 2025, and 2024, respectively | 2,000 | 1,000 | 3,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 62 | 53 | 52 | 51 | 48 | |
| Accumulated deficit | −63 | −50 | −40 | −31 | −21 | |
| Accumulated other comprehensive loss | −272,000 | −202,000 | −203,000 | −254,000 | −18,000 | |
| TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | −1 | 3 | 12 | 19 | 27 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | 3 | 5 | 13 | 20 | 28 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-08-31 |
|---|---|---|---|---|---|---|
| Net loss | −13 | −10 | — | — | — | |
| Net change in fair value of digital assets | 62,000 | 0 | — | — | — | |
| Non-cash lease expense | 35,000 | 33,000 | 40,000 | 39,000 | 7,000 | |
| Loss on extinguishment of debt | 825,000 | 0 | — | — | — | |
| Amortization of debt discounts and debt issuance costs | 146,000 | 0 | — | — | — | |
| Amortization of debt discounts and debt issuance costs - related party | 62,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 129,000 | 457,000 | 430,000 | −195,000 | −239,000 | |
| Accounts payable and accrued liabilities | 1 | 449,000 | 296,000 | −10,000 | −3,000 | |
| Accounts payable - related parties | 283,000 | 31,000 | −23,000 | 33,000 | 0 | |
| Accrued interest | 48,000 | 0 | — | — | — | |
| Accrued interest - related party | 21,000 | 0 | — | — | — | |
| Fixed cash payments related to operating leases | −35,000 | −30,000 | −40,000 | −43,000 | −2,000 | |
| Net cash used in operating activities | −9 | −8 | −8 | −8 | −6 | |
| Purchase of digital assets | −250,000 | 0 | — | — | — | |
| Proceeds from disposition of digital assets | 188,000 | 0 | — | — | — | |
| Investment in trading marketable securities | 0 | −481,000 | −14 | −13 | −6 | |
| Proceeds from disposition of marketable securities | 0 | 8 | 16 | 16 | 3 | |
| Net cash (used in) provided by investing activities | −62,000 | 8 | 4 | 3 | −3 | |
| Proceeds from issuance of common shares for cash, net | 6 | 112,000 | 567,000 | 0 | 8 | |
| Proceeds from issuance of convertible notes, net | 419,000 | 0 | — | — | — | |
| Proceeds from issuance of convertible notes, net - related party | 189,000 | 0 | — | — | — | |
| Proceeds from exercise of warrants | 132,000 | 0 | — | 0 | 6 | |
| Repayment of convertible note | −24,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 7 | 112,000 | 567,000 | 0 | 14 | |
| Effect of exchange rate changes on cash | −23,000 | −8,000 | 60,000 | −224,000 | −45,000 | |
| Net change in cash and cash equivalents | −2 | −477,000 | −4 | −5 | 4 | |
| Cash paid for interest | 0 | 0 | 0 | 0 | 0 | |
| Cash paid for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Initial recognition of the right-of-use asset and lease liability | 0 | 111,000 | 0 | 20,000 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro